R&D channel feed – Endpoints News

R&D channel feed

EMA backs seven therapies, including Merck's Ebola vaccine

6 years ago

Merck is taking the ax to its US operations, cutting 500 jobs in its latest reorganization

6 years ago

PhI fizzle forces Syros to spike its lead drug, triggering another rout on shares

6 years ago

Mirati preps its first look at their KRAS G12C contender, and they have to clear a high bar for success

6 years ago

UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach — and it won't be easy

6 years ago

The FDA will hustle up an expedited review for AstraZeneca’s next shot at a blockbuster cancer drug franchise

6 years ago

Incyte's cash cow Jakafi chugs along with positive frontline results for GVHD

6 years ago

With biosimilar threat under control (for now), Roche savors demand for its new drugs

6 years ago

Cell therapy player GammaDelta spins off Adaptate to direct body's surveillance system

6 years ago

Ipsen splurges $25M on its second rare disease drug pact of the year, with more on the way

6 years ago

CSL accuses rival Pharming of participating in a scheme to rip off IP on HAE while recruiting senior R&D staffer

6 years ago

Eli Lilly’s first PhIII showdown for their $1.6B cancer drug just flopped — what now?

6 years ago

Alexion pays $930M to buy out Achillion and its promising companion drug to Soliris

6 years ago

The $102B club: The top 15 R&D spenders in the global biopharma business — 2019 edition

6 years ago

Can CBD temper Parkinson's-related psychosis? UK researchers will look for answers in PhII study

6 years ago

Gilead vet Alessandro Riva steers Glenmark's biotech spinoff on independent course

6 years ago

That big neurosciences R&D group Eli Lilly built is being dismantled, with layoffs and parts shipped home

6 years ago

Surprising Wall Street, Reata unveils positive pivotal data on Friedreich’s ataxia drug

6 years ago

US mulls tariffs on Swiss drug exports, weighing on Novartis and Roche – report

6 years ago

In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic

6 years ago

A predator's world? Top analyst sees the 'haves' and the 'haven'ts' diverge as biotech bubbles form — and collapse

6 years ago

Cell therapy startup raises $16 million to fund its quest for the Holy Grail in regenerative medicine

6 years ago

Pelosi drug pricing bill promises savings, but could gag R&D — CBO analysis

6 years ago

Pfizer takes aim at a flagship franchise at Sanofi and Regeneron — and scores a few direct hits

6 years ago

First page Previous page 229 230 231232233 234 235 Next page Last page